nodes	percent_of_prediction	percent_of_DWPC	metapath
Entacapone—UGT1A9—Arylamine metabolism—NAT2—head and neck cancer	0.036	0.232	CbGpPWpGaD
Entacapone—Parkinsonism—Fluorouracil—head and neck cancer	0.0127	0.015	CcSEcCtD
Entacapone—COMT—Estrogen metabolism—GSTM1—head and neck cancer	0.0123	0.0793	CbGpPWpGaD
Entacapone—COMT—Estrogen metabolism—CYP1A1—head and neck cancer	0.0117	0.0752	CbGpPWpGaD
Entacapone—Blister—Hydroxyurea—head and neck cancer	0.0111	0.0132	CcSEcCtD
Entacapone—Numbness—Vinblastine—head and neck cancer	0.0106	0.0126	CcSEcCtD
Entacapone—Sensory loss—Vinblastine—head and neck cancer	0.0102	0.012	CcSEcCtD
Entacapone—Gastrointestinal symptom NOS—Fluorouracil—head and neck cancer	0.00982	0.0116	CcSEcCtD
Entacapone—Duodenal ulcer—Docetaxel—head and neck cancer	0.00863	0.0102	CcSEcCtD
Entacapone—Hepatic enzyme increased—Hydroxyurea—head and neck cancer	0.00848	0.01	CcSEcCtD
Entacapone—Heartburn—Fluorouracil—head and neck cancer	0.00839	0.00994	CcSEcCtD
Entacapone—Blister—Fluorouracil—head and neck cancer	0.00801	0.00949	CcSEcCtD
Entacapone—Phlebitis—Vinblastine—head and neck cancer	0.00741	0.00878	CcSEcCtD
Entacapone—UGT1A9—Estrogen metabolism—GSTM1—head and neck cancer	0.00739	0.0475	CbGpPWpGaD
Entacapone—Foetor hepaticus—Docetaxel—head and neck cancer	0.00735	0.0087	CcSEcCtD
Entacapone—Rash maculo-papular—Hydroxyurea—head and neck cancer	0.00729	0.00864	CcSEcCtD
Entacapone—Myocardial ischaemia—Fluorouracil—head and neck cancer	0.00718	0.00851	CcSEcCtD
Entacapone—COMT—Phase II conjugation—NAT2—head and neck cancer	0.00702	0.0451	CbGpPWpGaD
Entacapone—UGT1A9—Estrogen metabolism—CYP1A1—head and neck cancer	0.007	0.045	CbGpPWpGaD
Entacapone—Numbness—Fluorouracil—head and neck cancer	0.00697	0.00825	CcSEcCtD
Entacapone—Sensory loss—Fluorouracil—head and neck cancer	0.00667	0.00789	CcSEcCtD
Entacapone—Disorientation—Hydroxyurea—head and neck cancer	0.00651	0.00771	CcSEcCtD
Entacapone—Hepatic failure—Hydroxyurea—head and neck cancer	0.00648	0.00767	CcSEcCtD
Entacapone—Herpes simplex—Fluorouracil—head and neck cancer	0.00627	0.00742	CcSEcCtD
Entacapone—Liver disorder—Docetaxel—head and neck cancer	0.00612	0.00724	CcSEcCtD
Entacapone—Dermatitis bullous—Hydroxyurea—head and neck cancer	0.00609	0.00722	CcSEcCtD
Entacapone—Haemoglobin decreased—Docetaxel—head and neck cancer	0.00606	0.00717	CcSEcCtD
Entacapone—Heartburn—Docetaxel—head and neck cancer	0.00606	0.00717	CcSEcCtD
Entacapone—Inflammation—Fluorouracil—head and neck cancer	0.00595	0.00705	CcSEcCtD
Entacapone—Blood creatinine increased—Hydroxyurea—head and neck cancer	0.00546	0.00646	CcSEcCtD
Entacapone—Angina pectoris—Vinblastine—head and neck cancer	0.00538	0.00637	CcSEcCtD
Entacapone—Oesophagitis—Fluorouracil—head and neck cancer	0.00528	0.00625	CcSEcCtD
Entacapone—Rash maculo-papular—Fluorouracil—head and neck cancer	0.00525	0.00622	CcSEcCtD
Entacapone—Myocardial ischaemia—Docetaxel—head and neck cancer	0.00519	0.00614	CcSEcCtD
Entacapone—Ageusia—Docetaxel—head and neck cancer	0.00515	0.00609	CcSEcCtD
Entacapone—Euphoric mood—Fluorouracil—head and neck cancer	0.00496	0.00588	CcSEcCtD
Entacapone—Depression—Vinblastine—head and neck cancer	0.00491	0.00581	CcSEcCtD
Entacapone—Acute coronary syndrome—Vinblastine—head and neck cancer	0.00485	0.00575	CcSEcCtD
Entacapone—Neuropathy peripheral—Vinblastine—head and neck cancer	0.00482	0.00571	CcSEcCtD
Entacapone—Myocardial infarction—Vinblastine—head and neck cancer	0.00482	0.00571	CcSEcCtD
Entacapone—Dysuria—Hydroxyurea—head and neck cancer	0.00471	0.00557	CcSEcCtD
Entacapone—Disorientation—Fluorouracil—head and neck cancer	0.00469	0.00555	CcSEcCtD
Entacapone—Agranulocytosis—Vinblastine—head and neck cancer	0.00459	0.00544	CcSEcCtD
Entacapone—Hyperbilirubinaemia—Docetaxel—head and neck cancer	0.00458	0.00543	CcSEcCtD
Entacapone—Weight increased—Hydroxyurea—head and neck cancer	0.00458	0.00542	CcSEcCtD
Entacapone—Haemoglobin—Vinblastine—head and neck cancer	0.00444	0.00526	CcSEcCtD
Entacapone—Haemorrhage—Vinblastine—head and neck cancer	0.00442	0.00523	CcSEcCtD
Entacapone—Neuropathy peripheral—Hydroxyurea—head and neck cancer	0.0044	0.00521	CcSEcCtD
Entacapone—Hypoaesthesia—Vinblastine—head and neck cancer	0.0044	0.00521	CcSEcCtD
Entacapone—Dermatitis bullous—Fluorouracil—head and neck cancer	0.00439	0.00519	CcSEcCtD
Entacapone—Pharyngitis—Vinblastine—head and neck cancer	0.00439	0.00519	CcSEcCtD
Entacapone—Inflammation—Docetaxel—head and neck cancer	0.0043	0.00509	CcSEcCtD
Entacapone—Hepatobiliary disease—Hydroxyurea—head and neck cancer	0.00425	0.00503	CcSEcCtD
Entacapone—UGT1A9—Phase II conjugation—NAT2—head and neck cancer	0.0042	0.027	CbGpPWpGaD
Entacapone—Gastrointestinal haemorrhage—Fluorouracil—head and neck cancer	0.00419	0.00496	CcSEcCtD
Entacapone—Hepatocellular injury—Docetaxel—head and neck cancer	0.00417	0.00494	CcSEcCtD
Entacapone—Phosphatase alkaline increased—Docetaxel—head and neck cancer	0.00417	0.00494	CcSEcCtD
Entacapone—COMT—Biological oxidations—NAT2—head and neck cancer	0.0041	0.0264	CbGpPWpGaD
Entacapone—Haemoglobin—Hydroxyurea—head and neck cancer	0.00405	0.0048	CcSEcCtD
Entacapone—COMT—Metapathway biotransformation—NAT2—head and neck cancer	0.00405	0.026	CbGpPWpGaD
Entacapone—Haemorrhage—Hydroxyurea—head and neck cancer	0.00403	0.00477	CcSEcCtD
Entacapone—Hallucination—Hydroxyurea—head and neck cancer	0.00401	0.00475	CcSEcCtD
Entacapone—Colitis—Docetaxel—head and neck cancer	0.004	0.00474	CcSEcCtD
Entacapone—Fluid retention—Docetaxel—head and neck cancer	0.00396	0.00469	CcSEcCtD
Entacapone—Ataxia—Fluorouracil—head and neck cancer	0.00394	0.00467	CcSEcCtD
Entacapone—Alopecia—Vinblastine—head and neck cancer	0.0039	0.00462	CcSEcCtD
Entacapone—Oesophagitis—Docetaxel—head and neck cancer	0.00381	0.00451	CcSEcCtD
Entacapone—Muscular weakness—Fluorouracil—head and neck cancer	0.0037	0.00438	CcSEcCtD
Entacapone—Dysphagia—Fluorouracil—head and neck cancer	0.00362	0.00429	CcSEcCtD
Entacapone—Ill-defined disorder—Vinblastine—head and neck cancer	0.00357	0.00423	CcSEcCtD
Entacapone—Alopecia—Hydroxyurea—head and neck cancer	0.00356	0.00422	CcSEcCtD
Entacapone—Angina pectoris—Fluorouracil—head and neck cancer	0.00353	0.00418	CcSEcCtD
Entacapone—Phlebitis—Docetaxel—head and neck cancer	0.00351	0.00416	CcSEcCtD
Entacapone—Blood alkaline phosphatase increased—Docetaxel—head and neck cancer	0.00348	0.00412	CcSEcCtD
Entacapone—Malaise—Vinblastine—head and neck cancer	0.00347	0.00411	CcSEcCtD
Entacapone—COMT—Phase II conjugation—GSTM1—head and neck cancer	0.00346	0.0223	CbGpPWpGaD
Entacapone—Vertigo—Vinblastine—head and neck cancer	0.00346	0.00409	CcSEcCtD
Entacapone—Leukopenia—Vinblastine—head and neck cancer	0.00344	0.00408	CcSEcCtD
Entacapone—Upper respiratory tract infection—Fluorouracil—head and neck cancer	0.00337	0.00399	CcSEcCtD
Entacapone—Hepatic failure—Docetaxel—head and neck cancer	0.00337	0.00399	CcSEcCtD
Entacapone—Convulsion—Vinblastine—head and neck cancer	0.00333	0.00395	CcSEcCtD
Entacapone—Hypertension—Vinblastine—head and neck cancer	0.00332	0.00393	CcSEcCtD
Entacapone—UGT1A9—Aryl Hydrocarbon Receptor Pathway—CYP1A1—head and neck cancer	0.00331	0.0213	CbGpPWpGaD
Entacapone—Ill-defined disorder—Hydroxyurea—head and neck cancer	0.00325	0.00385	CcSEcCtD
Entacapone—Pneumonia—Fluorouracil—head and neck cancer	0.00325	0.00385	CcSEcCtD
Entacapone—Discomfort—Vinblastine—head and neck cancer	0.00324	0.00383	CcSEcCtD
Entacapone—Hot flush—Docetaxel—head and neck cancer	0.00323	0.00383	CcSEcCtD
Entacapone—Menopausal symptoms—Docetaxel—head and neck cancer	0.00321	0.0038	CcSEcCtD
Entacapone—Atrial fibrillation—Docetaxel—head and neck cancer	0.00319	0.00378	CcSEcCtD
Entacapone—Acute coronary syndrome—Fluorouracil—head and neck cancer	0.00318	0.00377	CcSEcCtD
Entacapone—Neuropathy peripheral—Fluorouracil—head and neck cancer	0.00317	0.00375	CcSEcCtD
Entacapone—Myocardial infarction—Fluorouracil—head and neck cancer	0.00317	0.00375	CcSEcCtD
Entacapone—Dermatitis bullous—Docetaxel—head and neck cancer	0.00317	0.00375	CcSEcCtD
Entacapone—Malaise—Hydroxyurea—head and neck cancer	0.00316	0.00375	CcSEcCtD
Entacapone—Conjunctivitis—Fluorouracil—head and neck cancer	0.00314	0.00372	CcSEcCtD
Entacapone—Urinary tract infection—Fluorouracil—head and neck cancer	0.00314	0.00372	CcSEcCtD
Entacapone—Leukopenia—Hydroxyurea—head and neck cancer	0.00314	0.00372	CcSEcCtD
Entacapone—Thrombocytopenia—Vinblastine—head and neck cancer	0.00307	0.00364	CcSEcCtD
Entacapone—Epistaxis—Fluorouracil—head and neck cancer	0.00305	0.00361	CcSEcCtD
Entacapone—Convulsion—Hydroxyurea—head and neck cancer	0.00304	0.0036	CcSEcCtD
Entacapone—Sinusitis—Fluorouracil—head and neck cancer	0.00303	0.00359	CcSEcCtD
Entacapone—Gastrointestinal haemorrhage—Docetaxel—head and neck cancer	0.00303	0.00358	CcSEcCtD
Entacapone—Pain in extremity—Docetaxel—head and neck cancer	0.00303	0.00358	CcSEcCtD
Entacapone—Agranulocytosis—Fluorouracil—head and neck cancer	0.00302	0.00357	CcSEcCtD
Entacapone—Anorexia—Vinblastine—head and neck cancer	0.00299	0.00354	CcSEcCtD
Entacapone—Unspecified disorder of skin and subcutaneous tissue—Hydroxyurea—head and neck cancer	0.00297	0.00351	CcSEcCtD
Entacapone—Discomfort—Hydroxyurea—head and neck cancer	0.00295	0.00349	CcSEcCtD
Entacapone—UGT1A9—PPARA activates gene expression—YAP1—head and neck cancer	0.00293	0.0188	CbGpPWpGaD
Entacapone—Haemoglobin—Fluorouracil—head and neck cancer	0.00292	0.00345	CcSEcCtD
Entacapone—Haemorrhage—Fluorouracil—head and neck cancer	0.0029	0.00343	CcSEcCtD
Entacapone—Hypoaesthesia—Fluorouracil—head and neck cancer	0.00289	0.00342	CcSEcCtD
Entacapone—Pharyngitis—Fluorouracil—head and neck cancer	0.00288	0.00341	CcSEcCtD
Entacapone—UGT1A9—Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)—YAP1—head and neck cancer	0.00286	0.0184	CbGpPWpGaD
Entacapone—Oedema—Hydroxyurea—head and neck cancer	0.00286	0.00339	CcSEcCtD
Entacapone—Ataxia—Docetaxel—head and neck cancer	0.00285	0.00337	CcSEcCtD
Entacapone—Paraesthesia—Vinblastine—head and neck cancer	0.00282	0.00334	CcSEcCtD
Entacapone—Nervous system disorder—Hydroxyurea—head and neck cancer	0.00281	0.00332	CcSEcCtD
Entacapone—UGT1A9—PPAR Alpha Pathway—CCND1—head and neck cancer	0.0028	0.018	CbGpPWpGaD
Entacapone—Thrombocytopenia—Hydroxyurea—head and neck cancer	0.0028	0.00332	CcSEcCtD
Entacapone—Skin disorder—Hydroxyurea—head and neck cancer	0.00278	0.00329	CcSEcCtD
Entacapone—Orthostatic hypotension—Docetaxel—head and neck cancer	0.00276	0.00327	CcSEcCtD
Entacapone—Anorexia—Hydroxyurea—head and neck cancer	0.00273	0.00323	CcSEcCtD
Entacapone—Decreased appetite—Vinblastine—head and neck cancer	0.00273	0.00323	CcSEcCtD
Entacapone—Cramp muscle—Docetaxel—head and neck cancer	0.00272	0.00323	CcSEcCtD
Entacapone—Toxic epidermal necrolysis—Docetaxel—head and neck cancer	0.00272	0.00323	CcSEcCtD
Entacapone—Pain—Vinblastine—head and neck cancer	0.00268	0.00318	CcSEcCtD
Entacapone—Constipation—Vinblastine—head and neck cancer	0.00268	0.00318	CcSEcCtD
Entacapone—Dysphagia—Docetaxel—head and neck cancer	0.00262	0.0031	CcSEcCtD
Entacapone—Feeling abnormal—Vinblastine—head and neck cancer	0.00259	0.00306	CcSEcCtD
Entacapone—Gastrointestinal pain—Vinblastine—head and neck cancer	0.00257	0.00304	CcSEcCtD
Entacapone—Alopecia—Fluorouracil—head and neck cancer	0.00256	0.00303	CcSEcCtD
Entacapone—Dyspnoea—Hydroxyurea—head and neck cancer	0.00255	0.00302	CcSEcCtD
Entacapone—Angina pectoris—Docetaxel—head and neck cancer	0.00255	0.00302	CcSEcCtD
Entacapone—Somnolence—Hydroxyurea—head and neck cancer	0.00255	0.00301	CcSEcCtD
Entacapone—Dyspepsia—Hydroxyurea—head and neck cancer	0.00252	0.00298	CcSEcCtD
Entacapone—Decreased appetite—Hydroxyurea—head and neck cancer	0.00249	0.00295	CcSEcCtD
Entacapone—Abdominal pain—Vinblastine—head and neck cancer	0.00248	0.00294	CcSEcCtD
Entacapone—Gastrointestinal disorder—Hydroxyurea—head and neck cancer	0.00247	0.00293	CcSEcCtD
Entacapone—Fatigue—Hydroxyurea—head and neck cancer	0.00247	0.00292	CcSEcCtD
Entacapone—UGT1A9—Biological oxidations—NAT2—head and neck cancer	0.00246	0.0158	CbGpPWpGaD
Entacapone—Pain—Hydroxyurea—head and neck cancer	0.00245	0.0029	CcSEcCtD
Entacapone—Constipation—Hydroxyurea—head and neck cancer	0.00245	0.0029	CcSEcCtD
Entacapone—UGT1A9—Metapathway biotransformation—NAT2—head and neck cancer	0.00242	0.0156	CbGpPWpGaD
Entacapone—UGT1A9—NRF2 pathway—TGFA—head and neck cancer	0.00238	0.0153	CbGpPWpGaD
Entacapone—Weight increased—Docetaxel—head and neck cancer	0.00238	0.00282	CcSEcCtD
Entacapone—Vision blurred—Fluorouracil—head and neck cancer	0.00238	0.00282	CcSEcCtD
Entacapone—Weight decreased—Docetaxel—head and neck cancer	0.00237	0.0028	CcSEcCtD
Entacapone—Feeling abnormal—Hydroxyurea—head and neck cancer	0.00236	0.00279	CcSEcCtD
Entacapone—Pneumonia—Docetaxel—head and neck cancer	0.00235	0.00278	CcSEcCtD
Entacapone—Hypersensitivity—Vinblastine—head and neck cancer	0.00231	0.00274	CcSEcCtD
Entacapone—Acute coronary syndrome—Docetaxel—head and neck cancer	0.0023	0.00272	CcSEcCtD
Entacapone—Myocardial infarction—Docetaxel—head and neck cancer	0.00229	0.00271	CcSEcCtD
Entacapone—Neuropathy peripheral—Docetaxel—head and neck cancer	0.00229	0.00271	CcSEcCtD
Entacapone—Conjunctivitis—Docetaxel—head and neck cancer	0.00227	0.00268	CcSEcCtD
Entacapone—Body temperature increased—Hydroxyurea—head and neck cancer	0.00226	0.00268	CcSEcCtD
Entacapone—Leukopenia—Fluorouracil—head and neck cancer	0.00226	0.00268	CcSEcCtD
Entacapone—Asthenia—Vinblastine—head and neck cancer	0.00225	0.00267	CcSEcCtD
Entacapone—Hepatobiliary disease—Docetaxel—head and neck cancer	0.00221	0.00261	CcSEcCtD
Entacapone—Epistaxis—Docetaxel—head and neck cancer	0.0022	0.0026	CcSEcCtD
Entacapone—Convulsion—Fluorouracil—head and neck cancer	0.00219	0.00259	CcSEcCtD
Entacapone—Agranulocytosis—Docetaxel—head and neck cancer	0.00218	0.00258	CcSEcCtD
Entacapone—Myalgia—Fluorouracil—head and neck cancer	0.00215	0.00255	CcSEcCtD
Entacapone—Chest pain—Fluorouracil—head and neck cancer	0.00215	0.00255	CcSEcCtD
Entacapone—Diarrhoea—Vinblastine—head and neck cancer	0.00215	0.00254	CcSEcCtD
Entacapone—Discomfort—Fluorouracil—head and neck cancer	0.00212	0.00251	CcSEcCtD
Entacapone—Hypersensitivity—Hydroxyurea—head and neck cancer	0.00211	0.0025	CcSEcCtD
Entacapone—Haemoglobin—Docetaxel—head and neck cancer	0.0021	0.00249	CcSEcCtD
Entacapone—Haemorrhage—Docetaxel—head and neck cancer	0.00209	0.00248	CcSEcCtD
Entacapone—Hepatitis—Docetaxel—head and neck cancer	0.00209	0.00248	CcSEcCtD
Entacapone—Hypoaesthesia—Docetaxel—head and neck cancer	0.00208	0.00247	CcSEcCtD
Entacapone—Confusional state—Fluorouracil—head and neck cancer	0.00208	0.00246	CcSEcCtD
Entacapone—Pharyngitis—Docetaxel—head and neck cancer	0.00208	0.00246	CcSEcCtD
Entacapone—Dizziness—Vinblastine—head and neck cancer	0.00208	0.00246	CcSEcCtD
Entacapone—UGT1A9—Phase II conjugation—GSTM1—head and neck cancer	0.00208	0.0134	CbGpPWpGaD
Entacapone—Urinary tract disorder—Docetaxel—head and neck cancer	0.00207	0.00245	CcSEcCtD
Entacapone—Oedema—Fluorouracil—head and neck cancer	0.00206	0.00244	CcSEcCtD
Entacapone—Asthenia—Hydroxyurea—head and neck cancer	0.00205	0.00243	CcSEcCtD
Entacapone—Urethral disorder—Docetaxel—head and neck cancer	0.00205	0.00243	CcSEcCtD
Entacapone—COMT—Biological oxidations—GSTM1—head and neck cancer	0.00203	0.013	CbGpPWpGaD
Entacapone—Nervous system disorder—Fluorouracil—head and neck cancer	0.00202	0.00239	CcSEcCtD
Entacapone—Thrombocytopenia—Fluorouracil—head and neck cancer	0.00202	0.00239	CcSEcCtD
Entacapone—Visual impairment—Docetaxel—head and neck cancer	0.00202	0.00239	CcSEcCtD
Entacapone—COMT—Metapathway biotransformation—GSTM1—head and neck cancer	0.002	0.0129	CbGpPWpGaD
Entacapone—Vomiting—Vinblastine—head and neck cancer	0.002	0.00236	CcSEcCtD
Entacapone—Erythema multiforme—Docetaxel—head and neck cancer	0.00198	0.00234	CcSEcCtD
Entacapone—UGT1A9—Fatty acid, triacylglycerol, and ketone body metabolism—YAP1—head and neck cancer	0.00197	0.0127	CbGpPWpGaD
Entacapone—Headache—Vinblastine—head and neck cancer	0.00197	0.00233	CcSEcCtD
Entacapone—Anorexia—Fluorouracil—head and neck cancer	0.00196	0.00233	CcSEcCtD
Entacapone—Diarrhoea—Hydroxyurea—head and neck cancer	0.00196	0.00232	CcSEcCtD
Entacapone—Eye disorder—Docetaxel—head and neck cancer	0.00196	0.00232	CcSEcCtD
Entacapone—Cardiac disorder—Docetaxel—head and neck cancer	0.00194	0.0023	CcSEcCtD
Entacapone—Flushing—Docetaxel—head and neck cancer	0.00194	0.0023	CcSEcCtD
Entacapone—Hypotension—Fluorouracil—head and neck cancer	0.00193	0.00228	CcSEcCtD
Entacapone—COMT—Biological oxidations—CYP1A1—head and neck cancer	0.00192	0.0124	CbGpPWpGaD
Entacapone—COMT—Metapathway biotransformation—CYP1A1—head and neck cancer	0.0019	0.0122	CbGpPWpGaD
Entacapone—Dizziness—Hydroxyurea—head and neck cancer	0.00189	0.00224	CcSEcCtD
Entacapone—Musculoskeletal discomfort—Fluorouracil—head and neck cancer	0.00188	0.00222	CcSEcCtD
Entacapone—Nausea—Vinblastine—head and neck cancer	0.00186	0.00221	CcSEcCtD
Entacapone—Insomnia—Fluorouracil—head and neck cancer	0.00186	0.00221	CcSEcCtD
Entacapone—Paraesthesia—Fluorouracil—head and neck cancer	0.00185	0.00219	CcSEcCtD
Entacapone—Alopecia—Docetaxel—head and neck cancer	0.00185	0.00219	CcSEcCtD
Entacapone—Dyspnoea—Fluorouracil—head and neck cancer	0.00184	0.00218	CcSEcCtD
Entacapone—Mental disorder—Docetaxel—head and neck cancer	0.00183	0.00217	CcSEcCtD
Entacapone—Somnolence—Fluorouracil—head and neck cancer	0.00183	0.00217	CcSEcCtD
Entacapone—UGT1A9—Aryl Hydrocarbon Receptor Pathway—IL2—head and neck cancer	0.00182	0.0117	CbGpPWpGaD
Entacapone—Malnutrition—Docetaxel—head and neck cancer	0.00182	0.00216	CcSEcCtD
Entacapone—Vomiting—Hydroxyurea—head and neck cancer	0.00182	0.00216	CcSEcCtD
Entacapone—Dyspepsia—Fluorouracil—head and neck cancer	0.00181	0.00215	CcSEcCtD
Entacapone—Rash—Hydroxyurea—head and neck cancer	0.00181	0.00214	CcSEcCtD
Entacapone—Dermatitis—Hydroxyurea—head and neck cancer	0.0018	0.00214	CcSEcCtD
Entacapone—Headache—Hydroxyurea—head and neck cancer	0.00179	0.00212	CcSEcCtD
Entacapone—Decreased appetite—Fluorouracil—head and neck cancer	0.00179	0.00212	CcSEcCtD
Entacapone—Dysgeusia—Docetaxel—head and neck cancer	0.00178	0.00211	CcSEcCtD
Entacapone—Gastrointestinal disorder—Fluorouracil—head and neck cancer	0.00178	0.00211	CcSEcCtD
Entacapone—Back pain—Docetaxel—head and neck cancer	0.00176	0.00209	CcSEcCtD
Entacapone—Pain—Fluorouracil—head and neck cancer	0.00176	0.00209	CcSEcCtD
Entacapone—Muscle spasms—Docetaxel—head and neck cancer	0.00175	0.00207	CcSEcCtD
Entacapone—Nausea—Hydroxyurea—head and neck cancer	0.0017	0.00201	CcSEcCtD
Entacapone—Feeling abnormal—Fluorouracil—head and neck cancer	0.0017	0.00201	CcSEcCtD
Entacapone—COMT—Metabolism—UROD—head and neck cancer	0.00169	0.0109	CbGpPWpGaD
Entacapone—UGT1A9—PPARA activates gene expression—CYP1A1—head and neck cancer	0.00165	0.0106	CbGpPWpGaD
Entacapone—Urticaria—Fluorouracil—head and neck cancer	0.00164	0.00194	CcSEcCtD
Entacapone—Syncope—Docetaxel—head and neck cancer	0.00163	0.00194	CcSEcCtD
Entacapone—Leukopenia—Docetaxel—head and neck cancer	0.00163	0.00193	CcSEcCtD
Entacapone—Body temperature increased—Fluorouracil—head and neck cancer	0.00163	0.00193	CcSEcCtD
Entacapone—UGT1A9—Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)—CYP1A1—head and neck cancer	0.00161	0.0104	CbGpPWpGaD
Entacapone—Palpitations—Docetaxel—head and neck cancer	0.00161	0.00191	CcSEcCtD
Entacapone—Loss of consciousness—Docetaxel—head and neck cancer	0.0016	0.0019	CcSEcCtD
Entacapone—Cough—Docetaxel—head and neck cancer	0.00159	0.00188	CcSEcCtD
Entacapone—Convulsion—Docetaxel—head and neck cancer	0.00158	0.00187	CcSEcCtD
Entacapone—Hypertension—Docetaxel—head and neck cancer	0.00157	0.00186	CcSEcCtD
Entacapone—Chest pain—Docetaxel—head and neck cancer	0.00155	0.00184	CcSEcCtD
Entacapone—Myalgia—Docetaxel—head and neck cancer	0.00155	0.00184	CcSEcCtD
Entacapone—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—head and neck cancer	0.00154	0.00182	CcSEcCtD
Entacapone—Hypersensitivity—Fluorouracil—head and neck cancer	0.00152	0.0018	CcSEcCtD
Entacapone—Dry mouth—Docetaxel—head and neck cancer	0.00152	0.0018	CcSEcCtD
Entacapone—Confusional state—Docetaxel—head and neck cancer	0.0015	0.00178	CcSEcCtD
Entacapone—Oedema—Docetaxel—head and neck cancer	0.00149	0.00176	CcSEcCtD
Entacapone—Shock—Docetaxel—head and neck cancer	0.00146	0.00173	CcSEcCtD
Entacapone—Nervous system disorder—Docetaxel—head and neck cancer	0.00146	0.00173	CcSEcCtD
Entacapone—Pruritus—Fluorouracil—head and neck cancer	0.00146	0.00173	CcSEcCtD
Entacapone—Thrombocytopenia—Docetaxel—head and neck cancer	0.00146	0.00172	CcSEcCtD
Entacapone—Skin disorder—Docetaxel—head and neck cancer	0.00144	0.00171	CcSEcCtD
Entacapone—Anorexia—Docetaxel—head and neck cancer	0.00142	0.00168	CcSEcCtD
Entacapone—Diarrhoea—Fluorouracil—head and neck cancer	0.00141	0.00167	CcSEcCtD
Entacapone—UGT1A9—Aryl Hydrocarbon Receptor Pathway—EGFR—head and neck cancer	0.00139	0.00897	CbGpPWpGaD
Entacapone—Hypotension—Docetaxel—head and neck cancer	0.00139	0.00165	CcSEcCtD
Entacapone—UGT1A9—NRF2 pathway—GSTM1—head and neck cancer	0.00138	0.0089	CbGpPWpGaD
Entacapone—Dizziness—Fluorouracil—head and neck cancer	0.00136	0.00161	CcSEcCtD
Entacapone—Musculoskeletal discomfort—Docetaxel—head and neck cancer	0.00136	0.0016	CcSEcCtD
Entacapone—Insomnia—Docetaxel—head and neck cancer	0.00135	0.00159	CcSEcCtD
Entacapone—Paraesthesia—Docetaxel—head and neck cancer	0.00134	0.00158	CcSEcCtD
Entacapone—Dyspnoea—Docetaxel—head and neck cancer	0.00133	0.00157	CcSEcCtD
Entacapone—Somnolence—Docetaxel—head and neck cancer	0.00132	0.00157	CcSEcCtD
Entacapone—Vomiting—Fluorouracil—head and neck cancer	0.00131	0.00155	CcSEcCtD
Entacapone—Dyspepsia—Docetaxel—head and neck cancer	0.00131	0.00155	CcSEcCtD
Entacapone—Rash—Fluorouracil—head and neck cancer	0.0013	0.00154	CcSEcCtD
Entacapone—Dermatitis—Fluorouracil—head and neck cancer	0.0013	0.00154	CcSEcCtD
Entacapone—Decreased appetite—Docetaxel—head and neck cancer	0.00129	0.00153	CcSEcCtD
Entacapone—Headache—Fluorouracil—head and neck cancer	0.00129	0.00153	CcSEcCtD
Entacapone—Gastrointestinal disorder—Docetaxel—head and neck cancer	0.00128	0.00152	CcSEcCtD
Entacapone—Fatigue—Docetaxel—head and neck cancer	0.00128	0.00152	CcSEcCtD
Entacapone—Pain—Docetaxel—head and neck cancer	0.00127	0.00151	CcSEcCtD
Entacapone—Constipation—Docetaxel—head and neck cancer	0.00127	0.00151	CcSEcCtD
Entacapone—Feeling abnormal—Docetaxel—head and neck cancer	0.00123	0.00145	CcSEcCtD
Entacapone—Nausea—Fluorouracil—head and neck cancer	0.00122	0.00145	CcSEcCtD
Entacapone—Gastrointestinal pain—Docetaxel—head and neck cancer	0.00122	0.00144	CcSEcCtD
Entacapone—UGT1A9—Biological oxidations—GSTM1—head and neck cancer	0.00121	0.00781	CbGpPWpGaD
Entacapone—UGT1A9—Metapathway biotransformation—GSTM1—head and neck cancer	0.0012	0.0077	CbGpPWpGaD
Entacapone—Body temperature increased—Docetaxel—head and neck cancer	0.00118	0.00139	CcSEcCtD
Entacapone—Abdominal pain—Docetaxel—head and neck cancer	0.00118	0.00139	CcSEcCtD
Entacapone—UGT1A9—Biological oxidations—CYP1A1—head and neck cancer	0.00115	0.0074	CbGpPWpGaD
Entacapone—UGT1A9—Metapathway biotransformation—CYP1A1—head and neck cancer	0.00114	0.0073	CbGpPWpGaD
Entacapone—UGT1A9—Fatty acid, triacylglycerol, and ketone body metabolism—CYP1A1—head and neck cancer	0.00111	0.00714	CbGpPWpGaD
Entacapone—Hypersensitivity—Docetaxel—head and neck cancer	0.0011	0.0013	CcSEcCtD
Entacapone—Asthenia—Docetaxel—head and neck cancer	0.00107	0.00126	CcSEcCtD
Entacapone—Pruritus—Docetaxel—head and neck cancer	0.00105	0.00125	CcSEcCtD
Entacapone—Diarrhoea—Docetaxel—head and neck cancer	0.00102	0.0012	CcSEcCtD
Entacapone—UGT1A9—Metabolism—UROD—head and neck cancer	0.00101	0.00651	CbGpPWpGaD
Entacapone—Dizziness—Docetaxel—head and neck cancer	0.000984	0.00116	CcSEcCtD
Entacapone—Vomiting—Docetaxel—head and neck cancer	0.000946	0.00112	CcSEcCtD
Entacapone—Rash—Docetaxel—head and neck cancer	0.000938	0.00111	CcSEcCtD
Entacapone—Dermatitis—Docetaxel—head and neck cancer	0.000937	0.00111	CcSEcCtD
Entacapone—Headache—Docetaxel—head and neck cancer	0.000932	0.0011	CcSEcCtD
Entacapone—Nausea—Docetaxel—head and neck cancer	0.000883	0.00105	CcSEcCtD
Entacapone—UGT1A9—Metabolism of lipids and lipoproteins—YAP1—head and neck cancer	0.000786	0.00505	CbGpPWpGaD
Entacapone—COMT—Transmission across Chemical Synapses—MAPK1—head and neck cancer	0.000718	0.00462	CbGpPWpGaD
Entacapone—COMT—Metabolism—NAT2—head and neck cancer	0.000702	0.00451	CbGpPWpGaD
Entacapone—COMT—Metabolism—DPYD—head and neck cancer	0.000615	0.00396	CbGpPWpGaD
Entacapone—COMT—Metabolism—YAP1—head and neck cancer	0.000584	0.00376	CbGpPWpGaD
Entacapone—COMT—Transmission across Chemical Synapses—HRAS—head and neck cancer	0.000577	0.00371	CbGpPWpGaD
Entacapone—COMT—Neuronal System—MAPK1—head and neck cancer	0.00055	0.00354	CbGpPWpGaD
Entacapone—UGT1A9—Metabolism of lipids and lipoproteins—GPX1—head and neck cancer	0.000447	0.00287	CbGpPWpGaD
Entacapone—UGT1A9—Metabolism of lipids and lipoproteins—CYP1A1—head and neck cancer	0.000442	0.00284	CbGpPWpGaD
Entacapone—COMT—Neuronal System—HRAS—head and neck cancer	0.000442	0.00284	CbGpPWpGaD
Entacapone—UGT1A9—Metabolism—NAT2—head and neck cancer	0.00042	0.0027	CbGpPWpGaD
Entacapone—UGT1A9—Metabolism—DPYD—head and neck cancer	0.000369	0.00237	CbGpPWpGaD
Entacapone—COMT—Metabolism—TYMS—head and neck cancer	0.000351	0.00226	CbGpPWpGaD
Entacapone—UGT1A9—Metabolism—YAP1—head and neck cancer	0.00035	0.00225	CbGpPWpGaD
Entacapone—COMT—Metabolism—GSTM1—head and neck cancer	0.000347	0.00223	CbGpPWpGaD
Entacapone—COMT—Metabolism—GPX1—head and neck cancer	0.000332	0.00214	CbGpPWpGaD
Entacapone—COMT—Metabolism—CYP1A1—head and neck cancer	0.000329	0.00211	CbGpPWpGaD
Entacapone—UGT1A9—Metabolism of lipids and lipoproteins—PTGS2—head and neck cancer	0.000263	0.00169	CbGpPWpGaD
Entacapone—UGT1A9—Metabolism of lipids and lipoproteins—PTEN—head and neck cancer	0.000229	0.00147	CbGpPWpGaD
Entacapone—UGT1A9—Metabolism—TYMS—head and neck cancer	0.00021	0.00135	CbGpPWpGaD
Entacapone—UGT1A9—Metabolism—GSTM1—head and neck cancer	0.000208	0.00134	CbGpPWpGaD
Entacapone—UGT1A9—Metabolism—GPX1—head and neck cancer	0.000199	0.00128	CbGpPWpGaD
Entacapone—UGT1A9—Metabolism—CYP1A1—head and neck cancer	0.000197	0.00127	CbGpPWpGaD
Entacapone—COMT—Metabolism—PTGS2—head and neck cancer	0.000195	0.00126	CbGpPWpGaD
Entacapone—COMT—Metabolism—PTEN—head and neck cancer	0.00017	0.0011	CbGpPWpGaD
Entacapone—UGT1A9—Metabolism of lipids and lipoproteins—PIK3CA—head and neck cancer	0.000162	0.00104	CbGpPWpGaD
Entacapone—COMT—Metabolism—PIK3CA—head and neck cancer	0.00012	0.000773	CbGpPWpGaD
Entacapone—UGT1A9—Metabolism—PTGS2—head and neck cancer	0.000117	0.000753	CbGpPWpGaD
Entacapone—UGT1A9—Metabolism—PTEN—head and neck cancer	0.000102	0.000657	CbGpPWpGaD
Entacapone—COMT—Metabolism—AKT1—head and neck cancer	9.82e-05	0.000632	CbGpPWpGaD
Entacapone—UGT1A9—Metabolism—PIK3CA—head and neck cancer	7.2e-05	0.000463	CbGpPWpGaD
Entacapone—UGT1A9—Metabolism—AKT1—head and neck cancer	5.88e-05	0.000378	CbGpPWpGaD
